Announcement
Announcement under Regulation 30 (LODR)-Updates on Acquisition 14 Oct - Laurus Labs invested INR 107.8 crore in KRKA Pharma via rights issue, holding stays at 49%.
Source: Bse
Laurus Labs Limited (LAURUSLABS)
Mid CapPharma stocks · Mid cap · NSE
Laurus Labs is a research-driven pharma and biotech company, a leader in APIs and FDFs for ARV, oncology, cardio, and gastro. It provides end-to-end CDMO services from early-stage to commercial production. Expanding into biotechnology, large molecules, cell, and gene therapies, it aims to improve global health.
Data qualityFresh enough for analysisQuote updated 21 Oct, 12:15 pm ISTDetails
Quote21 Oct, 12:15 pm IST
Base fundamentals16 Oct 2026 · screener
Latest result24 Jul, 08:18 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
87Strong Bullfull bull SMA stack · SMA20 +6.5% / mo · MACD − · near 52W high · sector +4.3pp vs Nifty 500 (3M)
Stock trend: 79
Sector RS: 99
Sector 3M: -1.7% vs Nifty 500 -6.0%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
LAURUSLABSD candles · FIT view+84.9%TODAY · PROVISIONALLatest price ₹2016.40 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-1.8%
RSI
53
MACD hist
-5.11
52W pos
94%
2026-10-21O ₹2052.90H ₹2079.80L ₹2015.70C ₹2016.40Vol 5.7L shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
LAURUSLABSNifty PharmaNifty 500
- LAURUSLABS
- +32.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +38.3 pp
Chart stats
19 Oct 2026- From 52W high
- -1.0%
- 52W range position
- 98%
- ATR (14)
- 2.4%
- Volume vs 20D
- 0.73x
- Avg traded value
- ₹297 Cr
- 20D price channel
- ₹1,952.1 - ₹2,089
₹2,089
₹843 - ₹2,089
₹49.5
Latest completed session
20-session average
25.8% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST33
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +29.0% · PAT +123.5% YoY
Technical
Strong Bull87
Price trend and sector-relative-strength timing.
Valuation
Legacy model-1478.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence79
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +29% YoY · PAT +123% YoY · margin expansion · +12% QoQ · operating leverage
Filed 24 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹2,026 Cr | +29.0% | +11.8% |
| EBITDA | ₹638 Cr | +67.0% | +24.6% |
| Operating margin | 32.0% | +800 bps | +400 bps |
| PAT | ₹362 Cr | +123.5% | +28.4% |
| PAT margin | 17.9% | +755 bps | +231 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 99.80
- P/B
- 20.55
- EV/EBITDA
- 49.11
- Market Cap
- 109062.00Cr
Profitability
- ROE
- 18.30%
- ROCE
- 17.80%
- ROA
- 10.38%
- Dividend Y
- 0.10%
Growth (CAGR)
- Revenue 5Y
- 7.00%
- EPS 5Y
- -2.00%
- Revenue 3Y
- 4.00%
- EPS 3Y
- 4.00%
Balance Sheet
- Debt/Equity
- 0.48
- Interest Coverage
- 11.09×
- Altman Z
- 8.13
- Book Value
- 98.20
Cash Flow
- FCF Yield
- 0.49%
- FCF Positive Y
- 4/5
- OCF
- 1624.00 Cr
- EPS TTM
- 20.24
Shareholding
- Promoter Hold
- 27.47%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 96%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 7,270+6.7% vs prev
Net Profit
₹ CrLatest: 358+121.0% vs prev
Return on Equity
%Latest: 8.0+103.0% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 53. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~5.6% over last month) — short-term momentum positive.
- RSI(14) at 53 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 3% off 52W high · 123% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
98
RS percentile
Stage 2 UptrendEstablished S2
1M return
+5.9%
3M return
+32.7%
6M return
+88.8%
1Y return
+115.6%
RS 1D
0
RS 20D
0
Sector rank
#1
Industry rank
#12
Stage evidence
- Price is 34.3% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +9.4%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
01 Apr 2026
S2 age
142 trading sessions
Sector
leading
Industry
weakening
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 253.82+1.48%
RS vs Nifty 500254
Valuation & peers
U-Score 33 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 33 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth5/25
Quality14/20
Balance Sheet6/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
33
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
33/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Quality contributes 14/20 to the score.
- Balance sheet contributes 6/15 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -1478.8%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
99.8
PB
20.6
EV/EBITDA
49.1
ROE
18.3%
ROCE
17.8%
FCF Yield
0.5%
Debt/Equity
0.5
MoS
-1478.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
33
Previous: 33
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-1478.8%
Previous: -1520.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
33
33
33
33
33
33
33
33
33
33
33
33
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹211.47
-853.5% MoS
Growth-justified P/E
6.3
Growth-justified Value
₹127.71
-1478.8% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MANKIND
Mid
Mankind Pharma Limited
Healthcare Services
match 167
34
45.5
13.1%
-4%
WATCHLIST
TORNTPHARM
Large
Torrent Pharmaceuticals Limited
Healthcare Services
match 155
42
78.2
27.4%
-59%
WATCHLIST
PPLPHARMA
Small
Piramal Pharma Limited
Healthcare Services
match 154
30
34.0
9.8%
-125%
OVERVALUED
MAXHEALTH
Large
Max Healthcare Institute Limited
Healthcare Services
match 154
35
67.5
12.7%
-497%
WATCHLIST
WOCKPHARMA
Small
Wockhardt Limited
Healthcare Services
match 154
20
79.4
6.1%
-2942%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-10-13T10:43:07.743Z
Management commentary snapshot
Laurus Labs reports strong 1Q FY27 results with revenue up 29% YoY to ₹2,026 Cr, driven by robust CDMO growth. EBITDA surged 66% YoY to ₹644 Cr, with margins expanding 700 bps to 31.8%, and Net Profit more than doubled, up 126% YoY to ₹368 Cr.
Strong 1Q FY27 performance, particularly in CDMO and margin expansion, supports the growth thesis. Significant CAPEX in advanced biologics and API/FDF capacity indicates continued investment for future growth, aligning with management's long-term vision for diversified portfolio and improved profitability.
Current business mix
FY26 Revenue by Business Division
Latest issuer-disclosed distribution across 2 reported categories.
CDMO31.0%
Affordable Medicines (GENERICS)69.0%
Growth engines
CDMO - Small Molecule
Strong visibility on late-stage projects & commercial API supplies, with a CAGR of 30% from FY20-26.
BIO - Precision Fermentation
Diversified growth and pipeline progress on larger global accounts, with traction in enzymatic technology applications.
Advanced Biologics (Gene/ADC)
Continued uptake in CAR-T volumes (>660 infusions as of Jun 2026) and in-licensed two ADC assets for India markets.
Affordable Medicines - FDF
KRKA JV FDF site progress on track, with Phase-I opening mid-2027, and a portfolio of 92 DMFs and 96 Dossiers filed.
Capacity and execution
Large-scale API Facility (Unit 7, Vizag)
Phase 1 of the new large-scale API facility (Unit 7, Vizag) is expected to start in 2027.
Enzyme Fermentation Plant (Unit 10, Vizag)
New commercial-scale fermentation plant (Unit 10, Vizag) expected to be online by end of 2026.
KRKA JV FDF Site (Hyderabad)
Phase-I of the KRKA JV FDF site in Hyderabad, focusing on High Potent and General OSD, is expected to open in mid-2027.
CAR-T Unit-2 (Mumbai)
2nd GMP production facility for CAR-T in Navi Mumbai operationalized in March 2026, with capacity for +2,500 treatments.
Tailwinds
Fast-growing CDMO market
Global CDMO small molecule market is projected at ~$85 bn with >7% CAGR (2025-34).
Increased outsourcing to India
Indian CDMO market is projected at ~$2 bn with >14% CAGR (2025-34) due to service capability advancement and increased outsourcing.
Healthy market dynamics for Affordable Medicines
Healthy market dynamics across the portfolio are supporting the orderbook for Affordable Medicines.
Risk radar
Macro-economic conditions
Changes in general market and macro-economic conditions in key global markets where we operate.
Competitive pressures
Increase in competitive pressures and technological developments.
Regulatory changes
Changes in laws and regulations applicable to customers, suppliers, and the pharmaceutical industry.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
YoY comparison is crucial to assess the underlying growth trends and margin expansion, especially given the significant increases in revenue, EBITDA, and net profit. QoQ comparison provides insight into sequential momentum and operational leverage from the previous quarter's performance.
Sector KPIs management disclosed
CDMO Revenue Growth
CDMO revenue growth +69% YoY in 1QFY27.
Affordable Medicines Revenue Growth
Affordable Medicines revenue growth +10% YoY in 1QFY27.
EBITDA Margin
EBITDA Margins at 31.8% in 1QFY27, up 700 bps YoY.
Gross Margin
Gross Margins at 62.7% in 1QFY27, up 330 bps YoY.
Management forward view
EBITDA Margin Guidance
Management is guiding for EBITDA margins of >30% from FY27+.
Continued CAPEX
Accelerated CAPEX of >₹3,000 Cr is proposed over FY27 and FY28 to meet growing demand, scale, and future growth.
CDMO Focus
Transformation continues with a consistent rise in CDMO revenue share and deepening client engagement on complex modalities.
ARV De-risking
The company's strategy of ARV de-risking continues.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| EBITDA Margin | 31.8% (1QFY27) | Sustained EBITDA margins above 30% as guided by management from FY27+. |
| CDMO Revenue Share | 31% (FY26) | Continued increase in CDMO revenue share as part of the business transformation. |
| Growth CAPEX Execution | >₹3,000 Cr proposed over FY27-28 | Timely execution and commissioning of key growth projects across API, Peptides, FDF, Fermentation, CGT, and ADC. |
| Asset Turnover Ratio (ATR) | 1.0x (1QFY27) | Improvement in ATR in the medium-term, aligning with the 6-year long-term average of 1.1x. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
79Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 88th percentile of the scored universe and 83rd percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 21 Oct 2026
management-trust-v1
180 docs text-extracted · 72 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
88th percentile
overall median 67 · Pharma: 83rd pctile, median 70 · Mid: 67th pctile, median 76
Evidence depth
Financial-only
180 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
77
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.5%.
- ▸4 years of positive FCF.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸OPM spread across recent quarters is 17%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Laurus Labs Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Updates on Acquisition 6 Oct - Laurus Labs invested ₹12.10 crore in KRPL rights issue; stake remains 26%.
Source: Bse
Investor presentationSep 2026
Sep 2026 · PPT
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Sep - Laurus Labs will attend ICICI Securities group investor meeting in Hyderabad on September 17, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 31 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Aug
Source: Bse
Concall transcriptJul 2026
Jul 2026 · Transcript
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 27 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Jun
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 Jun
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 4 Jun
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.